ARCHIVES

Phase III Nexavar Trial Fails Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 37 No. 8 | August 29, 2014

Download PDF Visit The Full Archive

Related Articles

Continuing Progress Reported On Breast Cancer Treatment; Mammography Controversy Cooled

November 26, 1976

FDA Commissioner Holds Up IND While Reviewing Toxicology Guidelines

August 14, 1981

Industry Groups Lobby for Lower Standards for FDA Approval

November 18, 2011

NCAB Cancer Centers committee recommends Ratio Cap To Limit Growth of Largest Grants

February 14, 1992

Revised Price Equivalent to Lower Dose of Avastin

November 8, 2012

Large, Conclusive Trials Provide Answers To Treatment Questions For GI Cancers

June 26, 2009